US · AAPG · BIOTECHNOLOGY
Ascentage Pharma Group International (AAPG) intrinsic value and stock valuation
$11.97as of 2026-11-21 · Mkt cap 1.57B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Ascentage Pharma Group International DCF and intrinsic value
InvestorsCraft values AAPG with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from AAPG’s statements →
Ascentage Pharma Group International Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2016–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Apogee Therapeutics, Inc. (APGE) $135.07
- CG Oncology Inc. (CGON) $79.47
- Xenon Pharmaceuticals Inc. (XENE) $37.04
- Celcuity Inc. (CELC) $53.35
- Legend Biotech Corporation (LEGN) $15.25
- Disc Medicine, Inc. (IRON) $75.14
- Ultragenyx Pharmaceutical Inc. (RARE) $16.48
- Zai Lab Limited (ZLAB) $21.03
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $558.5M | $980.7M | $222M | $209.7M | $27.9M |
| Operating income | -$-1.18B | -$-369.73M | -$-872.64M | -$-849.81M | -$-869.84M |
| Net income | -$-1.21B | -$-405.43M | -$-925.64M | -$-882.92M | -$-782.42M |
| EPSd | -$-13.58M | -$-5.37M | -$-52.47M | -$-53.58M | -$-49.18M |
| Operating cash flow | -$-1.17B | -$-111.36M | -$-726.08M | -$-653.91M | -$-604.68M |
| Capital expenditure | -$-27.57M | -$-24.29M | -$-56.84M | -$-236.96M | -$-436.63M |
| Free cash flow | -$-1.2B | -$-135.65M | -$-782.92M | -$-890.88M | -$-1.04B |
| Total assets | $3.97B | $2.62B | $2.5B | $2.83B | $2.94B |
| Total debt | $1.98B | $1.67B | $1.8B | $1.79B | $1.08B |
| Net debt | -$-490.68M | $431.9M | $726.3M | $317.1M | -$-622.6M |
| Total equity | $1.34B | $274.2M | $70.6M | $408.7M | $1.23B |
| Cash and short-term investments | $2.47B | $1.24B | $1.07B | $1.48B | $1.71B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $558.5M | $980.7M | $222M | $209.7M | $27.9M |
| Cost of revenue | $131.7M | $29.1M | $30.5M | $22M | $3.33M |
| Gross profit | $426.8M | $951.6M | $191.4M | $187.7M | $24.6M |
| Research and development expenses | $1.08B | $947.3M | $707M | $743.1M | $766.5M |
| Selling, general and administrative expenses | $522.7M | $383.1M | $376.5M | $328M | $191.3M |
| Other expenses | $0.00 | -$-9.07M | -$-19.36M | -$-33.6M | $0.00 |
| Operating expenses | $1.61B | $1.32B | $1.06B | $1.04B | $957.8M |
| Cost and expenses | $1.74B | $1.35B | $1.09B | $1.06B | $961.1M |
| Interest income | $79.9M | $37.8M | $32.4M | $9.73M | $7.11M |
| Interest expense | $52.6M | $64.5M | $96.1M | $52.8M | $16.7M |
| Depreciation and amortization | $84.1M | $93.2M | $93.2M | $47.4M | $17.2M |
| Ebitda | -$-1.1B | -$-237.63M | -$-743.61M | -$-786.97M | -$-798.34M |
| Operating income | -$-1.18B | -$-369.73M | -$-872.64M | -$-849.81M | -$-869.84M |
| Total other income/expenses, net | -$-23.21M | -$-25.52M | -$-60.23M | -$-37.36M | $37.6M |
| Income before tax | -$-1.2B | -$-395.25M | -$-932.86M | -$-887.17M | -$-832.25M |
| Income tax expense | $6.75M | $10.4M | -$-7.15M | -$-4.25M | -$-49.83M |
| Net income | -$-1.21B | -$-405.43M | -$-925.64M | -$-882.92M | -$-782.42M |
| Weighted average shares outstanding | $89M | $75.5M | $17.6M | $16.5M | $15.9M |
| Weighted average diluted shares outstanding | $89M | $75.5M | $17.6M | $16.5M | $15.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $2.47B | $1.24B | $1.07B | $1.48B | $1.71B |
| Net receivables | $253.1M | $99.1M | $163.5M | $61.5M | $54.1M |
| Inventory | $28.6M | $6.6M | $16.2M | $9.45M | $3.93M |
| Total current assets | $2.95B | $1.47B | $1.34B | $1.64B | $1.89B |
| Property, plant and equipment, net | $829.6M | $905.9M | $957.2M | $650M | $854.3M |
| Goodwill and intangible assets | $90.7M | $100.7M | $110.1M | $109M | $85.1M |
| Long-term investments | $37.1M | $33.9M | $19M | $18.5M | $27.8M |
| Total non-current assets | $1.02B | $1.14B | $1.16B | $1.19B | $1.05B |
| Total assets | $3.97B | $2.62B | $2.5B | $2.83B | $2.94B |
| Accounts payable | $106.8M | $92M | $72.4M | $95.6M | $70.9M |
| Short-term debt | $1.22B | $779.1M | $616.4M | $518.4M | $49.5M |
| Deferred revenue | $37.5M | $54.1M | $38.4M | $24.4M | $0.00 |
| Total current liabilities | $1.64B | $1.17B | $934.2M | $881.2M | $361.1M |
| Long-term debt | $757.7M | $889.4M | $1.18B | $1.27B | $1.03B |
| Deferred revenue, non-current | $216.9M | $276M | $287.6M | $218.6M | $243.3M |
| Total non-current liabilities | $986.6M | $1.18B | $1.5B | $1.54B | $1.34B |
| Capital lease obligations | $14.9M | $30.2M | $22.7M | $17.2M | $17.9M |
| Total liabilities | $2.63B | $2.34B | $2.43B | $2.42B | $1.71B |
| Common stock | $260K | $210K | $200K | $180K | $180K |
| Retained earnings | $0.00 | -$-5.77B | -$-5.37B | -$-4.44B | -$-3.56B |
| Accumulated other comprehensive income (loss) | $1.33B | -$-510.59M | -$-504.46M | -$-518.51M | -$-550.95M |
| Total equity | $1.34B | $274.2M | $70.6M | $408.7M | $1.23B |
| Total investments | $37.1M | $33.9M | $19M | $18.5M | $27.8M |
| Total debt | $1.98B | $1.67B | $1.8B | $1.79B | $1.08B |
| Net debt | -$-490.68M | $431.9M | $726.3M | $317.1M | -$-622.6M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-1.24B | -$-395.25M | -$-932.86M | -$-887.17M | -$-832.25M |
| Depreciation and amortization | $86.5M | $93.2M | $93.2M | $62.9M | $28.3M |
| Stock-based compensation | $20.9M | $20.9M | $31.5M | $22.1M | $47M |
| Change in working capital | -$-143.5M | $111M | -$-9.15M | $104.4M | -$-74.91M |
| Accounts receivable | -$-169.79M | $62.8M | -$-91.54M | -$-390K | -$-53.97M |
| Inventory | -$-26.2M | $9.57M | -$-6.72M | -$-5.52M | -$-3.93M |
| Accounts payable | $14.8M | $19.5M | -$-23.11M | $24.7M | $0.00 |
| Net cash provided by operating activities | -$-1.17B | -$-111.36M | -$-726.08M | -$-653.91M | -$-604.68M |
| Investments in property, plant and equipment | -$-27.57M | -$-24.29M | -$-46.11M | -$-203.29M | -$-435.42M |
| Acquisitions, net | -$-43.34M | -$-25.52M | -$-20M | -$-20M | -$-36.2M |
| Net cash used for investing activities | -$-1B | -$-362.04M | $21.9M | -$-384.61M | -$-466.52M |
| Common stock issued | $2.3B | $533.9M | $470.1M | $0.00 | $1.3B |
| Common stock repurchased | -$-9.04M | $0.00 | -$-5.92M | -$-26.78M | -$-25.87M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $2.54B | $314.8M | $368.8M | $619.3M | $1.78B |
| Net change in cash | $302.7M | -$-144.95M | -$-307.59M | -$-361.25M | $686.9M |
| Cash at end of period | $1.2B | $893.1M | $1.04B | $1.35B | $1.71B |
| Operating cash flow | -$-1.17B | -$-111.36M | -$-726.08M | -$-653.91M | -$-604.68M |
| Capital expenditure | -$-27.57M | -$-24.29M | -$-56.84M | -$-236.96M | -$-436.63M |
| Free cash flow | -$-1.2B | -$-135.65M | -$-782.92M | -$-890.88M | -$-1.04B |
Line items
Line items
Line items
About Ascentage Pharma Group International
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.
- CEO
- Dajun Yang
- Employees
- 767
- Beta
- 0.66
Explore
Frequently asked questions
What is the intrinsic value of Ascentage Pharma Group International (AAPG)?
Ascentage Pharma Group International (AAPG) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is AAPG undervalued?
AAPG trades at a price of $11.97 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.